Chimerix (CMRX) on Watch as Merck's (MRK) Letermovir Phase 3 Met Primary Endpoint n CMV Prevention

October 19, 2016 7:44 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Chimerix (Nasdaq: CMRX) shares are on watch after Merck (NYSE: MRK) announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary endpoint. The global, multicenter, randomized, placebo-controlled study evaluated the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT).

In December 2016, Chimerix announced that its Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT) did not achieve its primary endpoint for the prevention of clinically significant cytomegalovirus (CMV) infection through Week 24 after transplant.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Trader Talk

Add Your Comment